TYMS/KRAS/BRAF molecular profiling predicts survival following adjuvant chemotherapy in colorectal cancer

Table 2 Clinicopathologic data for colorectal cancer patients treated with adjuvant chemotherapy

Clinicopathologic data	Total (n = 130)
Median age (range)	67 (37-88)
Male	79 (60.8)
Primary site
Rectum	60 (46.2)
Positive lymph nodes	76 (58.5)
Stage according to AJCC
I	1 (0.8)
II	54 (41.5)
III	75 (57.7)
Histological grade
I + II	83 (63.8)
III + IV	47 (36.2)
KRAS mutation	48 (36.9)
BRAF V600E mutation	5 (3.8)
TYMS LOH	34 (26.2)
Overall survival
Deaths n (%)	45 (34.6)
Mean time month (95%CI)	110.0 (99.5-120.5)
Disease-free survival
Events n (%)	51 (39.2)
Mean time month (95%CI)	100.1 (88.3-112.0)
Median follow up in months (range)	71.2 (0.5-156.8)

AJCC: American Joint Committee on Cancer 7^th edition; TYMS: Thymidylate synthase gene; LOH: Loss of heterozygosity; CI: Confidence interval.